Active Immunomodulation IS ONE OF THE MOST promising approaches in modern precision medicine. To bring this to the next level, we at ingineeon develop first-in-class cytokine-based immunotherapeutics.
Our therapeutics have breakthrough potential in infectious diseases, immuno-oncology and autoimmunity.
Ingineeon is a Munich-based biotech company. Its pipeline is built on world-leading research at the Technical University of Munich. Our therapeutics are based on advanced molecular engineering
and have been validated in fully human ex vivo patient studies. In a defined path forward, we at ingineeon will soon bring our first-in-class immunotherapeutics to the clinics for the benefit of patients in need.
